205 related articles for article (PubMed ID: 35172048)
1. Emerging Treatments in Schizophrenia.
Correll CU; Abi-Dargham A; Howes O
J Clin Psychiatry; 2022 Feb; 83(1):. PubMed ID: 35172048
[TBL] [Abstract][Full Text] [Related]
2. Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment.
Azargoonjahromi A
Clin Drug Investig; 2024 Jun; ():. PubMed ID: 38904739
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
Kaul I; Sawchak S; Walling DP; Tamminga CA; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
JAMA Psychiatry; 2024 May; ():. PubMed ID: 38691387
[TBL] [Abstract][Full Text] [Related]
4. Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia.
Højlund M; Correll CU
Expert Opin Investig Drugs; 2022 Dec; 31(12):1279-1290. PubMed ID: 36533396
[TBL] [Abstract][Full Text] [Related]
5. Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders.
Kuvarzin SR; Sukhanov I; Onokhin K; Zakharov K; Gainetdinov RR
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509616
[TBL] [Abstract][Full Text] [Related]
6. Beyond dopamine: Novel strategies for schizophrenia treatment.
Dudzik P; Lustyk K; Pytka K
Med Res Rev; 2024 Apr; ():. PubMed ID: 38653551
[TBL] [Abstract][Full Text] [Related]
7. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics.
Lobo MC; Whitehurst TS; Kaar SJ; Howes OD
Neurosci Biobehav Rev; 2022 Jan; 132():324-361. PubMed ID: 34838528
[TBL] [Abstract][Full Text] [Related]
8. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.
Achtyes ED; Hopkins SC; Dedic N; Dworak H; Zeni C; Koblan K
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1543-1556. PubMed ID: 37165101
[TBL] [Abstract][Full Text] [Related]
9. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities.
Krogmann A; Peters L; von Hardenberg L; Bödeker K; Nöhles VB; Correll CU
CNS Spectr; 2019 Aug; 24(S1):38-69. PubMed ID: 31482779
[TBL] [Abstract][Full Text] [Related]
10. A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.
Koblan KS; Kent J; Hopkins SC; Krystal JH; Cheng H; Goldman R; Loebel A
N Engl J Med; 2020 Apr; 382(16):1497-1506. PubMed ID: 32294346
[TBL] [Abstract][Full Text] [Related]
11. Muscarinic Receptor Activators as Novel Treatments for Schizophrenia.
Paul SM; Yohn SE; Brannan SK; Neugebauer NM; Breier A
Biol Psychiatry; 2024 Mar; ():. PubMed ID: 38537670
[TBL] [Abstract][Full Text] [Related]
12. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
Brannan SK; Sawchak S; Miller AC; Lieberman JA; Paul SM; Breier A
N Engl J Med; 2021 Feb; 384(8):717-726. PubMed ID: 33626254
[TBL] [Abstract][Full Text] [Related]
13. Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal.
Dean B
Expert Opin Investig Drugs; 2023; 32(12):1113-1121. PubMed ID: 37994870
[TBL] [Abstract][Full Text] [Related]
14. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats.
Synan C; Bowen C; Heal DJ; Froger-Colléaux C; Beardsley PM; Dedic N; Hopkins SC; Campbell U; Koblan KS
Drug Alcohol Depend; 2022 Feb; 231():109261. PubMed ID: 35033729
[TBL] [Abstract][Full Text] [Related]
15. A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia.
Kane JM
J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5 Suppl 1):S1-S13. PubMed ID: 36099402
[TBL] [Abstract][Full Text] [Related]
16. Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results.
Breier A; Brannan SK; Paul SM; Miller AC
Psychopharmacology (Berl); 2023 May; 240(5):1191-1198. PubMed ID: 37036495
[TBL] [Abstract][Full Text] [Related]
17. New Developments in the Treatment of Schizophrenia: An Expert Roundtable.
Kantrowitz JT; Correll CU; Jain R; Cutler AJ
Int J Neuropsychopharmacol; 2023 May; 26(5):322-330. PubMed ID: 36932673
[TBL] [Abstract][Full Text] [Related]
18. [Antipsychotics with no dopamine receptor blockade; promise or hype?].
Vinkers CH
Ned Tijdschr Geneeskd; 2020 Dec; 164():. PubMed ID: 33332053
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials.
Le GH; Gillissie ES; Rhee TG; Cao B; Alnefeesi Y; Guo Z; Di Vincenzo JD; Jawad MY; March AM; Ramachandra R; Lui LMW; McIntyre RS
Expert Opin Investig Drugs; 2023 May; 32(5):401-415. PubMed ID: 37096491
[TBL] [Abstract][Full Text] [Related]
20. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
